A blood and marrow transplant and cellular therapy programme at the University of Missouri's cancer centre in Columbia, treating blood cancers with transplants and CAR T-cell therapy.
This is a hospital programme inside an academic health system, not a private regenerative medicine clinic, and the distinction matters for anyone comparing the two. University of Missouri Health Care runs a Blood and Marrow Transplant and Cellular Therapy Program based at its Ellis Fischel Cancer Center in Columbia, in the middle of the state. The treatment it provides is established, regulated cancer medicine for defined blood diseases, not an injection-based therapy for joint pain.
The site states that autologous transplants, in which a patient's own blood-forming stem cells are collected, stored and returned to them after high-dose treatment, are currently available for adults, and that allogeneic transplants using cells from a donor are in development for adult patients. That is a useful distinction for a patient to understand, because the two procedures differ substantially in risk and in aftercare. The pages reviewed do not specify whether cells are collected from circulating blood, from bone marrow directly, or from umbilical cord blood.
Alongside transplantation the programme offers CAR T-cell therapy, in which a patient's own immune T cells are genetically modified so that they recognise cancer cells. The site says six different CAR T-cell therapy options are currently available, with plans to expand. These are licensed products used within strict eligibility criteria at accredited centres, which again separates this programme from the unlicensed cell treatments offered elsewhere in this directory.
The conditions named are leukaemia, lymphoma, multiple myeloma and other blood disorders. The pages reviewed name no individual physicians and state no accreditation, and nothing is published about cost, although the site says clinical transplant coordinators help patients with insurance coverage, which indicates that treatment is expected to be funded through insurance rather than paid for privately. A patient would need to ask about accreditation status, which physicians would lead their care, and how far the programme has progressed with donor transplants.
The conditions named are blood cancers and blood disorders for which transplantation and cell therapy are established treatment.
The site describes collecting and storing a patient's own blood-forming stem cells for return after treatment, and separately offering CAR T-cell therapy using the patient's own modified immune cells.
The site describes the programme rather than naming clinicians.
The programme is based at the Ellis Fischel Cancer Center, part of University of Missouri Health Care in Columbia, which serves the middle of the state. This is a full academic hospital setting with inpatient capacity, intensive care support and cell collection and storage facilities, which is materially different from the outpatient clinics that make up most of this directory. The pages reviewed do not state the programme's accreditation status.
No prices are published. The site refers to clinical transplant coordinators who help patients with insurance coverage, which indicates that treatment is expected to be funded through health insurance rather than paid for privately, as is normal for transplantation and CAR T-cell therapy in the United States. A patient should ask the programme directly about approval and any out-of-pocket costs.
Profile compiled from information published on the clinic's own website and from the StemCell Registry directory record. Details may change; confirm directly with the clinic before making decisions.